title: The evaluation of a new 7-day gonadotropin-releasing hormone agonist protocol in the controlled ovarian hyperstimulation for in vitro fertilization.
abstract: OBJECTIVE
  Gonadotropin-releasing hormone agonist (GnRHa) was used in the controlled ovarian hyperstimulation (COH) for the in vitro fertilization program. However, the traditional long protocol demanded more human menopause gonadotropin (hMG) and sometimes causes unnecessary delay in the procedure. A new 7-day GnRHa/hMG protocol required to conserve cost and time is thus evaluated for better outcome.
  
  
  METHODS
  Sixty consecutive IVF candidates less than 40 years of age were recruited for the study. Cases with severe male factor or polycystic ovarian disease were excluded. The perspective candidates were divided into two groups, one received the traditional, GnRHa2hMG protocol and the other received the new 7-day regimen.
  
  
  RESULTS
  When comparing the results in pregnancy rate (33.3% vs 30%), cleavage rate (75.7% vs 75.5%), and the number of oocyte obtained (5.96 +/- 0.91 vs 6.63 +/- 0.90), the 7-day GnRHa/hMG protocol is as good as those of the traditional regimen. The amount of hMG used nevertheless was significantly less (21.48 +/- 0.78 vs 50.59 +/- 2.07).
  
  
  CONCLUSIONS
  The new regimen will surely reduce the cost to relieve patient's financial burden and to increase patient's comfort.
authors.affiliation: Department of Obstetrics and Gynecology, Veterans General Hospital-Taipei, Taiwan, ROC.
authors.forename: T S
authors.initials: TS
authors.lastname: Yang
authors.forename: S H
authors.initials: SH
authors.lastname: Tsan
authors.forename: B C
authors.initials: BC
authors.lastname: Wang
authors.forename: S P
authors.initials: SP
authors.lastname: Chang
authors.forename: H T
authors.initials: HT
authors.lastname: Ng
mesh_terms: D000328:Adult; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004341:Drug Evaluation; D004624:Embryo Transfer; D004958:Estradiol / Q000097:blood; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage*; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000819:agonists*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008596:Menotropins / Q000008:administration & dosage*; D009865:Oocytes / Q000502:physiology; D010053:Ovary / Q000187:drug effects* / Q000502:physiology; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D013094:Spermatozoa / Q000502:physiology
chemical_list: D004338:Drug Combinations; D005300:Fertility Agents, Female; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D008596:Menotropins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone